<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Infective Endocarditis MeG-CLS-058</title>
  <style type="text/css">
@charset "UTF-8";.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script>{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> a:active,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> a:hover{outline-width:0}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> a:hover{text-decoration:underline}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> a:not([href]){color:inherit;text-decoration:none}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> strong{font-weight:600}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> h1,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> h2,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> h3,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> h4,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> h5,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> h3{font-size:1.25em}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> h4{font-size:1em}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> h5{font-size:.875em}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> h6{font-size:.85em;color:#6a737d}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> img{border-style:none}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> svg:not(:root){overflow:hidden}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> hr::before{display:table;content:""}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> hr::after{display:table;clear:both;content:""}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> [type=checkbox]{box-sizing:border-box;padding:0}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> *{box-sizing:border-box}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> blockquote{margin:0}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> ol,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> ul{padding-left:2em}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> ol ol,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> ul ol{list-style-type:lower-roman}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> ol ol,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> ol ul,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> ul ol,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> ul ul{margin-top:0;margin-bottom:0}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> ol ol ol,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> ol ul ol,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> ul ol ol,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> ul ul ol{list-style-type:lower-alpha}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> li>p{margin-top:16px}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> li+li{margin-top:.25em}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> dd{margin-left:0}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> dl{padding:0}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> dl dd{padding:0 16px;margin-bottom:16px}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> blockquote,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> dl,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> ol,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> p,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> pre,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> table,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> ul{margin-top:0;margin-bottom:16px}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> blockquote>:first-child{margin-top:0}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> blockquote>:last-child{margin-bottom:0}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> table th{font-weight:600}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> table td,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> table tr:nth-child(2n){background-color:#f6f8fa}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> code::after,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> code::before{letter-spacing:-.2em;content:" "}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> .highlight{margin-bottom:16px}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> .highlight pre{margin-bottom:0;word-break:normal}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> .highlight pre,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> pre code::after,.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> pre code::before{content:normal}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> .task-list-item{list-style-type:none}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> .task-list-item+.task-list-item{margin-top:3px}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script> .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script>::before{display:table;content:""}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script>::after{display:table;clear:both;content:""}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script>>:first-child{margin-top:0!important}.markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script>>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
<script src="myScript.js"></script><link rel="stylesheet" href="myStyle.css"></head>
<<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script>>
<article class="markdown-<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script>">
<h1 id="infective-endocarditis">Infective Endocarditis</h1>
<h2 id="executive-summary"><em>Executive summary</em></h2>
<h2 id="introduction">Introduction</h2>
<h2 id="infective-endocarditis-ie-refers-to-infection-of-the-endocardial-surface-of-the-heart-it-usually-refers-to-infection-of-one-or-more-heart-valves-or-infection-of-an-intracardiac-device.">Infective endocarditis (IE) refers to infection of the endocardial surface of the heart; it usually refers to infection of one or more heart valves or infection of an intracardiac device.</h2>
<h3 id="target-users">Target users</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Doctors</p>
</div></li>
</ul>
<h3 id="target-area-of-use">Target area of use </h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Ward</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>OPD</p>
</div></li>
</ul>
<h3 id="key-areas-of-focus-new-additions-changes">Key areas of focus / New additions / Changes </h3>
<p>This guideline focuses on the diagnostic criteria and the anti- infective therapy for infective endocarditis. It covers treatment of bacterial and fungal infective endocarditis.</p>
<p>Users should take particular note of the indications for surgical intervention.</p>
<h2 id="limitations">Limitations</h2>
<p>Patients requiring surgical intervention may need to be referred to surgeons outside of the Gambia.</p>
<h2 id="risk-factors">Risk factors</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Age &gt;60 years</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Male sex</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Poor dentition or dental infection</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Heart problem: Structural heart disease, Valvular disease, Congenital heart disease</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Prosthetic valve</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>History of prior IE</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>HIV infection</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Injection drug use</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Chronic hemodialysis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Intravascular device</p>
</div></li>
</ul>
<h2 id="pathogen">Pathogen</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p><em>S.aureus</em> (31%)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Viridans group streptococci (17%)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Enterococci (11%)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Coagulade-negative staphylococci (11%)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p><em>Streptococcus bovis</em> (7%)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Other streptococci (5%)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Non-HACEK gram-negative bacteria (2%)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Fungi (2%)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>HACEK (2%): organisms in this category include a number of fastidious gram-negative bacilli: <em><strong>H</strong>aemophilus aphrophilus,</em> <em><strong>A</strong>ctinobacillus actinomycetemcomitans,</em> <em><strong>C</strong>ardiobacterium hominis</em>; <em><strong>E</strong>ikenella corrodens</em>; and <em><strong>K</strong>ingella kingae</em></p>
</div></li>
</ul>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h2>
<p>Fever is the most common symptom (&gt; 90%). It is often associated with chills, anorexia, and weight loss.</p>
<p>Other common symptoms include malaise, headache, myalgia, arthralgia, night sweats, abdominal pain, dyspnoea, cough, and pleuritic pain. Note that these symptoms are non-specific and there may be not much more than a sense that something is wrong.</p>
<p>Patients with IE associated with dental infection may report tooth pain or related symptoms.</p>
<h2 id="examination-findings">Examination findings</h2>
<p>Cardiac murmurs are the most common sign. Supportive signs include splenomegaly and cutaneous manifestations such as petechiae or splinter hemorrhages.</p>
<p>Relatively uncommon clinical manifestations that are highly suggestive of IE include:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p><strong>Janeway lesions</strong> – Nontender erythematous macules on the palms and soles.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p><strong>Osler nodes</strong> – Tender subcutaneous violaceous nodules mostly on the pads of the fingers and toes, which may also occur on the thenar and hypothenar eminences.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p><strong>Roth spots</strong> – Exudative, edematous hemorrhagic lesions of the retina with pale centers.</p>
</div></li>
</ul>
<p>Complications as presenting symptoms:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Cardiac complications (&gt;50%) – Valvular insufficiency, heart failure, and others</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Neurologic complications (&gt;40%) – Embolic stroke, intracerebral hemorrhage, brain abscess, and others</p>
</div>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Septic emboli (&gt;25%) – Infarction of kidneys, spleen, and other organs. In right-sided endocarditis, septic pulmonary emboli may be seen.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Spleen embolic: radiating abdominal pain that goes to the left shoulder</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Renal: flank pain in the groin with possible pus or blood in the urine</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Brain (stroke): changes in neuro status, confusion, speech difficulty</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Pulmonary: chest pain, shortness of breath, dyspnea, decreased oxygen saturation</p>
</div></li>
</ul></li>
<li><div data-custom-style="List Paragraph">
<p>Metastatic infection – vertebral osteomyelitis, septic arthritis, psoas abscess</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Systemic immune reaction – glomerulonephritis</p>
</div></li>
</ul>
<p><strong>Diagnosis</strong></p>
<p>This is based on a combination of clinical suspicion, the presence of risk factors, examination findings and the following investigations:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Urine dipstick (looking especially for blood)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>ECG</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>ECHO</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Blood cultures – 3 samples each from 2 or more different sites at least 1 hour apart and ideally taking 10 ml of blood each time. These must be completed before antibiotics are started.</p>
</div></li>
</ul>
<p>These results can be combined to formally make a diagnosis of IE using modified Duke criteria. Note that some patients will not meet these criteria in our setting, but will still have a high suspicion of IE and no alternative treatable diagnosis, so will need to be treated for IE anyway.</p>
<h3 id="modified-duke-criteria">Modified Duke criteria</h3>
<table>
<thead>
<tr class="header">
<th><strong>Major criteria</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><em><strong>Positive blood culture</strong></em> with common endocarditis pathogen (grown in 2 separate cultures)</td>
</tr>
<tr class="even">
<td><p><em><strong>Evidence of endocardial involvement</strong></em> either</p>
<div data-custom-style="List Paragraph">
<blockquote>
<p>Echocardiogram vegetation <strong>OR</strong></p>
</blockquote>
</div>
<div data-custom-style="List Paragraph">
<blockquote>
<p><span class="underline">New</span> valvular regurgitation</p>
</blockquote>
</div></td>
</tr>
<tr class="odd">
<td><strong>Minor criteria</strong></td>
</tr>
<tr class="even">
<td>One of the risk factors</td>
</tr>
<tr class="odd">
<td>Fever (Documented temp =&gt; 38.0°C)</td>
</tr>
<tr class="even">
<td><em><strong>Vascular phenomena:</strong></em> major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, or Janeway lesions</td>
</tr>
<tr class="odd">
<td><em><strong>Immunologic phenomena:</strong></em> Glomerulonephritis, Osler nodes, Roth spots, or rheumatoid factor</td>
</tr>
<tr class="even">
<td><em><strong>Microbiologic evidence:</strong></em> Positive blood cultures that do not meet major criteria <strong>OR</strong> serologic evidence of active infection with organism consistent with IE</td>
</tr>
</tbody>
</table>
<p><strong>Definite IE:</strong> 2 major criteria <em>or</em> 1 major + 3 minor criteria <em>or</em> 5 minor criteria</p>
<p><strong>Possible IE:</strong> 1 major + 1 minor criteria <em>or</em> 3 minor criteria</p>
<h2 id="management">Management </h2>
<h3 id="antibiotic-therapy">Antibiotic therapy</h3>
<table>
<thead>
<tr class="header">
<th></th>
<th><strong>Native heart valve</strong></th>
<th><strong>Prosthetic heart valve(s)</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Empiric</p>
<p><em>(paediatric dosing)</em></p></td>
<td><p>Ampicillin 2 g (<em>50 mg/kg</em>) q4h IV <strong>AND</strong></p>
<p>Gentamicin 3 mg/kg OD IV</p></td>
<td><p>Ampicillin 2 g (<em>50 mg/kg</em>) q4h IV <strong>AND</strong></p>
<p>Gentamicin 5 mg/kg OD IV <strong>AND</strong></p>
<p>Rifampicin 600 mg (<em>10 mg/kg</em>) BD PO</p></td>
</tr>
</tbody>
</table>
<p><span class="underline">Note on usage of gentamicin for IE</span></p>
<p>The gentamicin dose is adjusted from UK guidelines (but is consistent with US / European guidelines) because we do not have access to the therapeutic drug monitoring necessary to safely dose gentamicin in a more than OD regimen.</p>
<p>eGFR must be calculated as soon as possible when gentamicin is started. If this is reduced below &lt; 50 ml/min, then the dose of gentamicin should be reduced to by 50%. All patients expected to receive gentamicin for more than 1 week must have their U&amp;Es checked 3 times per week and the gentamicin stopped as soon as there is any change in the results.</p>
<h3 id="blood-culture-positive">Blood culture positive</h3>
<table>
<thead>
<tr class="header">
<th></th>
<th><strong>Native heart valve</strong></th>
<th><strong>Prosthetic heart valve(s)</strong></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Pathogen</strong></td>
<td><strong>Dose</strong> (<em>paediatric dosing)<strong>)</strong></em></td>
<td><strong>Duration (weeks)</strong></td>
<td><strong>Dose</strong> <em>paediatric dosing<strong>)</strong></em></td>
<td><strong>Duration (weeks)</strong></td>
</tr>
<tr class="even">
<td><em>S.aureus</em> (Methicillin sensitive)</td>
<td>Cloxacillin 2 g (<em>50 mg/kg</em>) QDS IV</td>
<td>4</td>
<td><p>Cloxacillin 2 g (<em>50 mg/kg</em>) QDS IV <strong>AND</strong></p>
<p>Rifampicin 600 mg (<em>10 mg/kg</em>) BD PO</p></td>
<td><p>6</p>
<p>6</p></td>
</tr>
<tr class="odd">
<td>MRSA</td>
<td>Requires vancomycin or teicoplanin and rifamipicin. Would be very difficult to treat in our setting.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><em>Streptococcus</em> spp</td>
<td><p>Benzylpenicillin 2.4 g (<em>35 mg/kg</em>) q4h IV <strong>AND</strong></p>
<p>Gentamicin 3 mg/kg OD IV</p></td>
<td><p>4-6</p>
<p>2</p></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><em>Enterococcus</em></td>
<td><p>Ampicillin 2 g (<em>30 mg/kg</em>) q4h IV <strong>AND</strong></p>
<p>Gentamicin 3 mg/kg OD IV</p></td>
<td><p>4-6</p>
<p>4-6</p></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td>HACEK</td>
<td><p>Ceftriaxone 2 g (<em>80 mg/kg</em>) OD IV <strong>AND</strong></p>
<p>Gentamicin 3 mg/kg OD IV</p></td>
<td><p>4-6</p>
<p>2</p></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<h3 id="blood-culture-negative">Blood culture negative</h3>
<p>It is not possible to distinguish between different causes of blood culture negative IE in our setting. Therefore, empiric treatment is used as below where good quality blood cultures taken before antibiotic therapy are negative and there is suspicion of possible infection with <em>Brucella</em>, <em>Coxiella burnetii</em> or <em>Bartonella</em>. Specialist advice should be sought about this as soon as possible.</p>
<table>
<thead>
<tr class="header">
<th><strong>Agent</strong></th>
<th><strong>Dose</strong> (<em>paediatric dosing)</em></th>
<th><strong>Duration (weeks)</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Empiric</td>
<td><p>Doxycycline 200 mg (<em>4.4 mg/kg</em>) OD PO <strong>AND</strong></p>
<p>Ceftriaxone 2 g (<em>80 mg/kg</em>) OD IV <strong>AND</strong></p>
<p>Gentamicin 3 mg/kg OD IV</p></td>
<td><p>6 (may need to be longer)</p>
<p>4</p></td>
</tr>
</tbody>
</table>
<p>Note doxycycline cannot be used below the age of 12 years.</p>
<h3 id="fungal-endocarditis">Fungal endocarditis</h3>
<p>Fungal endocarditis is most common in patients with prosthetic valves, but also occurs in intravenous drug abusers, neonates and immunocompromised patients. Mortality is very high (50%), and treatment necessitates combined antifungal administration and surgical valve replacement.</p>
<p>Unfortunately, we do not have access to the necessary drugs, so the best we can do is use high dose fluconazole.</p>
<table>
<thead>
<tr class="header">
<th><strong>Agent</strong></th>
<th><strong>Primary</strong></th>
<th><strong>After patient is stable</strong></th>
<th><strong>Duration</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Dose</strong> <em>(paediatric dosing)</em></td>
<td>Fluconazole 1200 mg <em>(18 mg/kg) OD PO</em></td>
<td>Fluconazole 800 mg (12 mg/kg) OD PO</td>
<td><p>For at least 6 weeks after surgery</p>
<p>*For patients who cannot undergo valve replacement; lifelong</p></td>
</tr>
</tbody>
</table>
<p>In case a patient has the means to purchase more effective drugs, they would need to be given amphotericin and flucytosine.</p>
<p><strong>Indications for Surgery</strong></p>
<p>Ideally, a surgical opinion should be sought for every patient with endocarditis. Unfortunately, this is not possible here for most patients. However, it may be possible to discuss children with endocarditis with the Chain of Hope team. The indications for surgery are listed below.</p>
<table>
<thead>
<tr class="header">
<th><strong>Heart Failure</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Aortic or mitral IE with:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Severe acute regurgitation or valve obstruction</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Persistent heart failure</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Refractory pulmonary oedema / cardiogenic shock</p>
</div></li>
</ul></td>
</tr>
<tr class="even">
<td><strong>Uncontrolled infection</strong></td>
</tr>
<tr class="odd">
<td><ul>
<li><div data-custom-style="List Paragraph">
<p>Abscess, false aneurysm, enlarging vegetation</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Persisting fever and positive blood culture for &gt; 10 days after commencing appropriate antimicrobial therapy</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Caused by fungi or multiresistant micro organisms</p>
</div></li>
</ul></td>
</tr>
<tr class="even">
<td><strong>Prevention of embolism</strong></td>
</tr>
<tr class="odd">
<td><ul>
<li><div data-custom-style="List Paragraph">
<p>Large vegetations (&gt; 10 mm) + embolic episodes</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Large vegetations (&gt; 10 mm) + other predictors of complicated cause</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Very large vegetation (&gt; 15 mm)</p>
</div></li>
</ul></td>
</tr>
</tbody>
</table>
<p><strong><br />
</strong></p>
<p><strong>Endocarditis Prophylaxis</strong></p>
<p><strong><span class="underline">Indication</span></strong>: A cardiac condition AND a procedure</p>
<p><strong>Cardiac conditions</strong>: Prosthetic valve, unrepaired cyanotic congenital heart disease, some patients with repaired congenital heart disease (check online for current guidance), previous infective endocarditis.</p>
<p><strong>Procedures</strong>:</p>
<ol type="1">
<li><div data-custom-style="List Paragraph">
<p>Dental procedure: manipulation of gingival tissue or periapical region of teeth or perforation of the oral mucosa.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Respiratory procedure: incision or biopsy of respiratory mucosa.</p>
</div></li>
</ol>
<p><strong>Regimens</strong>: Amoxicillin 2 g IV (Penicillin allergic: clindamycin 600 mg PO)</p>
<p><strong>Timing</strong>: 30-60 min before the procedures</p>
<h2 id="key-issues-for-nursing-care">Key Issues for Nursing care</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Monitor vital signs especially temperature, heart rate, blood pressure, oxygen saturation.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Educate the patient about:</p>
</div></li>
</ul>
<ol type="1">
<li><div data-custom-style="List Paragraph">
<p>The need to inform other healthcare practitioners about history of endocarditis because they are at risk for it again and will need prophylactic antibiotics prior to invasive procedures</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>How to take or administer antibiotics (complete all doses)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>The importance of good oral care.</p>
</div></li>
</ol>
<h2 id="references">References</h2>
<p>Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: Journal of Antimicrobial Chemotherapy, Volume 67, Issue 2, 1 February 2012, Pages 269–289</p>
<p>2015 ESC Guidelines for the management of infective endocarditis: European Heart Journal (2015) 36, 3075–3123 doi:10.1093/eurheartj/ehv319</p>
<p>Up to date: Antimicrobial therapy of prosthetic valve endocarditis: last updated: Sep 06, 2018</p>
<p>Up to date: Clinical manifestations and evaluation of adults with suspected native valve endocarditis last updated: Apr 27, 2018</p>
<p>Up to date: Epidemiology, risk factors, and microbiology of infective endocarditis: last updated: Oct 26, 2018.</p>
<p>Up to date: Infective endocarditis in children: last updated: Nov 29, 2017.</p>
<p>Endocarditis NCLEX Review| Registered Nurse RN. com| NCLEX Review. Web. 19 Aug. 2016</p>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th>Name: Eriko Ikeda</th>
<th>Date: 16 November 2018</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Name: Karen Forrest</td>
<td>Date: 21 November 2018</td>
</tr>
<tr class="even">
<td></td>
<td>Name: Thushan de Silva</td>
<td>Date: 21 November 2018</td>
</tr>
<tr class="odd">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="even">
<td>1.0</td>
<td>New document</td>
<td>31 January 2021</td>
</tr>
<tr class="odd">
<td>1.1</td>
<td>Executive summary added</td>
<td>31 January 2021</td>
</tr>
<tr class="even">
<td>Review Comments (<em>if applicable)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script>>
</html>
